Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Cervical Cancer
Interventions: HPV self-sampling kit, Culturally-targeted Fear Appeal Message, Fear Appeal Message, Interview; Diagnostic Test · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Nodal Marginal Zone Lymphoma
Interventions: Not listed
Lead sponsor: International Extranodal Lymphoma Study Group (IELSG); Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Rochester, Minnesota • New York, New York + 1 more

Conditions: Pseudobulbar Affect (PBA)
Interventions: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 45
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more

Conditions: Hypoparathyroidism
Interventions: MBX 2109, Placebo; Drug · Other
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 27
States / cities: Sacramento, California • Jacksonville, Florida • Miami, Florida + 22 more

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 49
States / cities: Litchfield Park, Arizona • Sun City, Arizona • Lancaster, California + 41 more

Conditions: Major Depressive Disorder, Depression
Interventions: REL-1017, Placebo; Drug
Lead sponsor: Levomecor Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 70
States / cities: Homewood, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more

Conditions: Arthritis, Rheumatoid
Interventions: Otilimab (GSK3196165), csDMARD(s); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 79
States / cities: Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more

Conditions: Moderate to Severe Asthma
Interventions: povorcitinib, placebo, ICS-LABA; Drug · Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • Bakersfield, California • Upland, California + 18 more

Conditions: Lung Cancer
Interventions: IPI-504; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more

Conditions: Vaccines, Meningococcal Vaccines
Interventions: rLP2086 and Gardasil, rLP2086, Gardasil; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 11 Years to 17 Years
Enrollment: 2,499 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 87
States / cities: Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more

Conditions: Rheumatoid Arthritis
Interventions: SAR441566, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 17
States / cities: Northridge, California • Upland, California • Jacksonville, Florida + 14 more

Conditions: Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions: AZD0120, SOC; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 8 more

Conditions: Biliary Cancer
Interventions: SPI-1620, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 3 more

Conditions: Acne Vulgaris
Interventions: FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam; Combination Product · Drug · Other
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: COPD plus CAPTURE education and patient-level information, COPD Education Only; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 80 Years
Enrollment: 2,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 8
States / cities: Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 397
States / cities: Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 14
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 11 more

Conditions: Depressive Disorder, Major
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Phoenix, Arizona • Glendale, California • Temecula, California + 20 more

Conditions: Migraine Disorders
Interventions: ALD403, Placebo; Biological
Lead sponsor: Alder Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 82
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Hematologic Malignancies
Interventions: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review; Biological · Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Arcadia, California • Los Angeles, California • Newport Beach, California + 16 more

Conditions: Kidney Transplantation
Interventions: Mycophenolate mofetil, Cyclosporine, Tacrolimus; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 57
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more

Search by objective public record fields.

Acceptability of Human Papillomavirus (HPV) Self-sampling Tools for Cervical Cancer Prevention

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

A Study of AZD0120 in Autoimmune Diseases

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

A Multicenter Assessment of ALD403 in Chronic Migraine

IVIG for Infection Prevention After CAR-T-Cell Therapy

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation